الفهرس 
ACKNOWLEDGMENTSOnly 14 pages are availabe for public view
 |  | from | 163 |  |  |
| | | from | 163 | | |
Abstract
Hepatitis B virus-associated glomerulonephritis remains one of the most common secondary glomerular diseases especially in endemic areas, although its incidence seems to decrease nowadays after the popularization of HBV vaccination.chronic infection with HBV in patients with chronic kidney disease represents a distinct and challenging clinical entity. The special characteristics of this patient group and the related changes in clinical course of liver disease often have long-term implications on morbidity and mortality and affect the patients’ management.The primary effort for HBV eradication and thus reduction of HBV-associated kidney disease is based on the global HBV immunization and the appropriate screening programmes. Nucleosides analogues with high genetic barrier to HBV resistance are the best options for HBV-positive patients with chronic kidney disease in order to minimize the consequences of HBV infection. Combination with immunosuppressive agents might be considered in cases of rapid renal function deterioration and/or severe proteinuria.